VRDN Stock Summary and Trading Ideas (Viridian Therapeutics | NASDAQ:VRDN)

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.

As of November 6, 2026, VRDN stock price declined to $28.49 with 4,139,711 million shares trading.

VRDN has a beta of -0.55, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.01 to the broad based SPY ETF.

VRDN has a market cap of $3.24 billion. This is considered a Mid Cap stock.

Last quarter Viridian Therapeutics reported $25,752 in Revenue and -$.81 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.21.

In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.

The top ETF exchange traded funds that VRDN belongs to (by Net Assets): IWM, XBI, VTI, VXF, IWN.

VRDN has outperformed the market in the last year with a price return of +16.7% while the SPY ETF gained +9.6%. VRDN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +35.2% and +24.8%, respectively, while the SPY returned -4.2% and -3.8%, respectively.

VRDN support price is $27.57 and resistance is $29.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.